SaNOtize Research and Development, the Canadian developer of the candidate, began phase 2 trials of the nasal spray in its home market after generating preclinical evidence of efficacy, including a rapid 95% reduction in viral load in rodents.

The clinical development program spread to the U.K. this week, where physicians began enrolling subjects in the first European assessment of the prospect.

COVID-19 nasal spray starts clinical development in the U.K.